Vicetin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vicetin

Quick Facts

Property Description
Active Ingredient Vinpocetine
Form Oral preparations (tablets), Injection solution
Pharmacological Class Cerebral Vasodilator, Nootropic Agent
General Purpose Supporting brain circulation and metabolism
Origin Semi-synthetic derivative of the indole alkaloid vincamine

What Type of Medicine is Vicetin and What is its Origin?

Vicetin is a medicinal product containing the active substance Vinpocetine, which is classified primarily as a cerebral vasodilator and is also recognized as a nootropic agent. Chemically, Vinpocetine is a semi-synthetic derivative of the indole alkaloid vincamine, a compound naturally found in the leaves of the Vinca minor plant. The resulting structure acts directly on the central nervous system, and its use in supporting brain function is clinically recognized across various pharmacological studies. This suggests the medicine is acknowledged for its role in influencing blood flow and metabolism within the brain.


Vicetin's Core Composition and Available Forms

Vicetin is a single-component preparation, relying solely on Vinpocetine as the active ingredient within its formulation. The product is typically supplied in two main forms: as an oral preparation, such as tablets, intended for consistent maintenance therapy, and as a sterile injection solution for intravenous administration when a rapid effect is required. Both forms utilize standard pharmaceutical carriers to ensure the effective systemic delivery of the therapeutic compound.


What is the General Purpose of Vinpocetine in the Body?

The general purpose of Vinpocetine is to support brain health by facilitating selective cerebral blood flow enhancement and providing important neuroprotective properties. Its mechanism involves inhibiting certain enzymes, which leads to the relaxation of smooth muscle in cerebral blood vessels, thereby increasing the supply of oxygen and essential nutrients to the brain tissue. Research into its fundamental actions confirms that Vinpocetine acts as a selective inhibitor of phosphodiesterase type 1 (PDE1) directly targeting a biochemical pathway to improve circulation within the brain. This strategy focuses on supporting the metabolic demands of the brain and preserving the integrity of neuronal cells.

Regulatory References

  1. cerebral vasodilator

What side effects are possible with Vicetin?

Possible Side Effects and Safety Information

The safety profile of Vicetin (Vinpocetine) is described in official regulatory documents using standardized frequency classifications and system-organ-class groupings. The majority of documented adverse reactions fall into the Uncommon category, meaning they are observed in less than 1 in 100 patients.

Documented Adverse Reactions

System-Organ Class (SOC) Examples of Officially Listed Effects Frequency Classification Examples
Nervous system Headaches, vertigo, sleep disturbances (insomnia, somnolence) Uncommon (Headaches, Vertigo)
Cardiac disorders Changes in ECG parameters (QT interval lengthening, ST segment reduction), tachycardia, ectopic beats Uncommon (ECG changes, Tachycardia)
Vascular disorders Changes in arterial blood pressure (often a decrease), face reddening (flushing) Uncommon (Blood pressure changes)
Gastrointestinal Nausea, heartburn, dryness of the oral mucosa Uncommon (Nausea, Heartburn)
Blood and lymphatic Leukopoenia; decrease in hematocrit and hemoglobin concentration Rare (Leukopoenia)

Safety Restrictions and Special Populations

Official prescribing information outlines specific situations where Vicetin is contraindicated due to documented safety risks. It must not be used in individuals with severe ischaemic heart disease or severe cardiac arrhythmia. Use is also restricted in the presence of acute bleeding in the central nervous system, such as hemorrhagic stroke.

For specific populations, use during pregnancy and lactation is strictly contraindicated because regulatory review has associated consumption with a potential for adverse reproductive effects, including miscarriage and fetal harm. The medicine is also contraindicated for use in children and adolescents due to a lack of sufficient safety data for this age group. Patients with advanced renal failure may require regulatory dose adjustments.

Overdose and Emergency Response

The official regulatory profile for Vicetin overdose is built upon documented clinical signs and the required emergency response.

Overdose with Vicetin may present with symptoms affecting multiple systems. Documented manifestations include gastrointestinal disturbances such as nausea and vomiting, alongside Central Nervous System effects like somnolence and agitation. The primary serious concern is the effect on the cardiovascular system, which can involve blood pressure changes, specifically the development of hypotension, and the risk of cardiac arrhythmia.

Due to the potential for severe cardiovascular outcomes, immediate medical attention is required upon suspicion of overdose, and emergency services must be contacted without delay. Hospital monitoring and observation are mandated for any individual who has taken an excessive amount.

Management of Vicetin overdose is universally described as symptomatic and supportive treatment. Regulatory guidance clarifies that no specific antidote is known to reverse the effects of the active ingredient, Vinpocetine. In cases of recent, massive oral ingestion, supportive measures may officially include gastric lavage or the administration of activated charcoal. The overall regulatory structure classifies this as a situation requiring mandatory medical stabilization and monitoring.

Therapeutic Uses of Vicetin

What Vicetin Treats: Main Uses and Benefits

Vicetin is commonly used in settings where supportive symptom management for conditions linked to cerebral circulation disturbances is appropriate. The medication is generally used for managing symptoms associated with vascular dementia, mild organic psychosyndromes, and chronic cerebral vascular insufficiency.

It helps address symptom clusters that may become disruptive, including memory disturbance, difficulties with attention and concentration, vascular-related dizziness and unsteady gait, and manifestations of certain audio-vestibular disorders like tinnitus and vertigo. Its therapeutic role is particularly relevant for assisting patients with maintaining functional stability during chronic phases and easing the overall symptom load.

“The supportive benefit of Vicetin may assist patients in coping more steadily with challenging sensory manifestations and chronic neurological discomfort.”


Quick Fact: Relief for Vascular-Related Symptoms

Symptom Category Therapeutic Focus Clinical Contexts
Cognitive Deficits Addressing memory and concentration issues Vascular dementia, post-stroke recovery
Balance/Auditory Supporting relief for vertigo, disequilibrium, and tinnitus Audio-vestibular disorders of vascular origin
Chronic Neurological Assisting with functional stability and comfort Chronic cerebral vascular insufficiency

Regulatory References

  1. EFDA Product Information Document

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Vicetin

The eligibility for Vicetin (Vinpocetine) is strictly defined by regulatory authorities, outlining specific patient populations that are permitted, restricted, or prohibited from using the medicine. Use of Vicetin is generally established for adults and older adults.


Absolute Contraindications

Vicetin is formally contraindicated and must not be used in the following populations and conditions:

  • Pediatric Use: Children and adolescents (under 18 years old) are prohibited due to insufficient data on safety and efficacy.
  • Reproductive Status: Women who are pregnant or breastfeeding.
  • Cardiac Conditions: Patients with severe pre-existing ischaemic heart disease or cardiac arrhythmia.
  • Hypersensitivity: Individuals with known hypersensitivity to Vinpocetine or other Vinca alkaloids.
  • Acute Events: Patients experiencing active or recent bleeding to the central nervous system, such as an acute hemorrhagic stroke.

Restricted and Conditional Use

Certain populations require special consideration or dose reduction as defined by the label:

  • Severe Renal Impairment: Doses should be reduced in patients diagnosed with severe kidney failure.
  • Metabolic Conditions: Oral preparations containing lactose should be avoided by patients with hereditary problems such as galactose intolerance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes clinically significant interactions with Vicetin that primarily involve the potential for bleeding risk and drug metabolism interference.

Documented Interacting Product Categories

Product Category Interacting Medicines (Explicitly Listed)
Anticoagulants (Blood Thinners) Warfarin (Coumadin)
Antiplatelet Drugs None explicitly listed (Category applies)
CYP2C9 Substrates None explicitly listed (Category applies)

Interaction Constraints and Requirements

The documented interaction profile is structured around two main mechanistic concerns. First, Vicetin may slow blood clotting, presenting a pharmacodynamic interaction that enhances the effects of other medications that also slow clotting. This effect necessitates caution in patients who are concurrently taking anticoagulant medications (such as Warfarin) or antiplatelet drugs. Specifically, co-administration with Warfarin is a clinically significant interaction requiring regular blood monitoring (Prothrombin Time/INR) and potential dose adjustment of the anticoagulant. Second, Vicetin may alter the rate at which the liver breaks down co-administered medications that are substrates of the Cytochrome P450 2C9 (CYP2C9) enzyme, a pharmacokinetic interaction that could change the concentrations and effects of these other drugs. Due to the risk of increased bleeding, regulatory information also imposes a timing-based restriction, requiring that Vicetin use be stopped at least 2 weeks before scheduled surgery.

Mechanism of Action

Modulation of Cerebral Blood Flow (Vascular Domain)

Vicetin acts by inhibiting the enzyme Phosphodiesterase Type 1 (PDE1), which is specifically concentrated in the smooth muscle surrounding blood vessels in the brain. This enzyme inhibition prevents the rapid hydrolysis of cyclic signaling nucleotides. The resulting increase in these molecules causes the relaxation of the vascular smooth muscle. This mechanism enhances perfusion pressure and causes selective cerebral vasodilation, resulting in an increased supply of oxygen and glucose to brain tissue.


Direct Neuronal Stabilization and Metabolism (Cellular Domain)

The molecule also engages in ion channel modulation, specifically acting as an inhibitor of Voltage-Dependent Sodium Channels (Na^+ channels) on nerve cell membranes. This action adjusts the neuronal membrane potential, reducing the cell's propensity for excessive depolarization. This Na^+ channel mechanism complements the PDE1 effect by directly ensuring neurons are functionally stabilized against overstimulation.


Control of Neuroinflammatory Signaling (Immune/Pathway Domain)

Vicetin influences the central nervous system's inflammatory response by modulating the NF-kappaB pathway, often through the inhibition of IkappaB kinase (IKK). This action suppresses the signaling cascade that typically leads to the activation and transcription of pro-inflammatory mediators. By dampening this response, the mechanism contributes to the downregulation of pro-inflammatory signals within the central nervous system.

Dosage and Administration Information

How Vicetin is Used

Vicetin (Vinpocetine) is administered through distinct routes depending on the treatment stage. The therapy typically follows a two-phase protocol: initial treatment using a parenteral solution, followed by long-term maintenance with oral tablets.


Administration Routes and Dosing

Vicetin is administered via the oral route for sustained therapy and via intravenous (IV) infusion or intramuscular (IM) injection for initial or acute management.

For oral maintenance, the standard adult dosing regimen is typically one 10 mg tablet, three times a day (TID), equating to a 30 mg total daily dose. For initial parenteral use, the dose may start at 20 mg daily via slow drip IV infusion and can be titrated up to 1 mg/kg body weight over several days.


Administration Conditions and Duration

Oral administration follows specific intake conditions: tablets must be taken after a meal to support proper absorption and should be swallowed whole with water.

Therapy is a long-term commitment. While therapeutic activity may begin within approximately one week, clinical improvement is often observed after six to twelve months of continuous oral treatment. For IV administration, the solution must be diluted and administered as a slow drip infusion; the solution is chemically incompatible with heparin and must not be mixed with it.


Population-Specific Use

No dosage adjustment is necessary for older adults. However, the dose must be reduced in patients with severe renal function impairment. Vicetin is not to be used in children and adolescents due to insufficient data.

Recent Clinical Evidence

Research evidence / Overview of studies


Drug Mechanism and Efficacy Studies

This section summarizes research that has explored the observed effects and the efficacy of Vicetin in studies for the specified condition.

The drug was studied in relation to its ability to affect inflammation and pain signals. Research has focused on the drug’s activity in models related to the specified condition.

  • Large-Scale Trial Findings One large-scale Randomized Controlled Trial (RCT) evaluated whether the drug was associated with changes in a primary symptom score compared to placebo. The study reported a measured difference in a primary symptom score when comparing the active treatment group to the placebo group. The mean difference in the score was reported as X points (95% CI: Y to Z).

  • Quality of Life Meta-Analysis Another study, a meta-analysis, examined the drug’s potential association with patients’ quality of life across several key domains. Findings described changes in some domains, but high variability between the included studies limits conclusions.


Pharmacokinetics and Specific Populations

This area of research explores how the drug is processed by the body and its effects in specific populations.

  • Elderly Patient Findings Furthermore, a smaller study investigated the processing and effects of the drug in elderly patients. The study noted observations of slower metabolism in this group compared to younger adults.

  • Dosing and Combination Use The research examined the drug across various dose levels. Research also explored whether combining the drug with standard treatment resulted in different outcomes.

  • Study Limitations The majority of available evidence is drawn from trials lasting six months or less. Therefore, data beyond six months are not available and are the subject of ongoing research.

  • Disclaimer This information is descriptive of the studies only.

Frequently Asked Questions (FAQ)

Common questions about Vicetin (FAQ)


Q: How quickly does Vicetin start working after taking it?

Regulatory information indicates that the active substance, Vinpocetine, reaches its highest concentration in the bloodstream shortly after administration. While this relates to the drug's absorption, it does not represent the full therapeutic effect. Achieving the clinical benefits described in studies is observed over a longer period of continuous treatment.

Q: How long does Vicetin stay in the body?

Pharmacokinetic studies, which describe how the body processes the medicine, indicate that the active substance has an elimination half-life of approximately five hours. This figure describes the time necessary for half of the substance to be eliminated from the body.

Q: Why do official documents warn about using Vicetin with alcohol?

Official sources advise caution with alcohol, noting that the combination has been associated with an increased possibility of certain adverse effects, such as dizziness or drowsiness.

Q: Can women who are planning to become pregnant use Vicetin?

Official safety warnings from regulatory bodies specifically advise women of childbearing potential not to use products containing the active ingredient, including when planning a pregnancy. The restriction is informed by safety data that describe a possibility for adverse reproductive effects or effects on a developing fetus.

Q: Is it normal to feel a bit dizzy after starting Vicetin?

Official lists of documented adverse reactions include effects such as vertigo and changes in blood pressure, which can be related to feelings of dizziness or light-headedness. These effects are generally classified as uncommon. It is noted that these sensations are possible, but not frequent, side effects.

Q: What is the typical timeframe for noticing the full effect of Vicetin?

Clinical studies summarized in official documents show that noticeable clinical improvement is typically observed after a patient has completed a continuous period of oral treatment. This timeframe is often specified as a range of several months, such as six to twelve months.

Q: Are there dietary restrictions required when taking Vicetin?

Official administration instructions state that oral tablets must be taken after a meal to help ensure proper absorption of the medicine. However, regulatory documents do not specify a list of food groups or specific dietary items that must be avoided while using the drug.

Q: Are there any common foods or drinks that interact with Vicetin?

Official information regarding interactions focuses on medicinal substances. Regulatory documents do not typically list specific, common foods or non-alcoholic beverages that create adverse interactions with the medicine.

Q: Is it safe to drive a car while taking Vicetin?

Official product information often includes a dedicated section on driving. Because uncommon side effects like dizziness and somnolence (drowsiness) are reported, the documents advise caution, stating that a patient's ability to safely drive or operate machinery may be impaired depending on their personal reaction to the drug.

Q: What happens if I miss a scheduled time to take Vicetin?

Patient information typically describes a procedure for a missed dose, which often involves taking the dose when remembered unless the next dose is due. This information advises against taking a double dose.

Q: Are there any long-term health concerns associated with Vicetin use?

Therapy with the drug is often intended for long-term use. However, some regulatory summaries note that the majority of existing clinical evidence has been drawn from trials lasting six months or less. Information on effects beyond this timeframe is generally considered limited or the subject of ongoing research.

Q: Is Vicetin available without a prescription?

In many regions where it has been approved as a medicinal product, the drug is designated by regulatory authorities as a prescription-only medicine. This requires it to be dispensed by a pharmacist with a valid prescription.

Q: Why do some people say Vicetin makes them feel tired?

Official adverse reaction reports include somnolence, which refers to drowsiness or a feeling of being tired, as an uncommon side effect of the medicine. The inclusion of this effect in the regulatory safety profile confirms that feeling tired is a documented, though infrequent, response to treatment.

Q: Does taking Vicetin mean I need to avoid certain activities?

Official documents describe the risk of potential impairment for tasks that require focus, like driving or operating machinery, due to the documented side effects of dizziness and drowsiness. No other mandatory activity restrictions are typically specified in regulatory information.

Q: Can Vicetin affect mood or cause emotional changes?

The official documentation does include categories for psychiatric disorders in its list of adverse reactions. Reported effects in this category may include insomnia or restlessness, but specific or broad mood or emotional changes are not typically listed as common effects in regulatory summaries.

Q: Does Vicetin interact with birth control pills?

The drug is known to potentially alter the rate at which the liver processes certain medications, specifically those metabolized by the CYP2C9 enzyme. If an oral contraceptive uses this pathway, an interaction could occur, although regulatory labels generally do not list birth control pills explicitly.

Q: Can people with high blood pressure safely use Vicetin?

Official safety data lists changes in arterial blood pressure as a possible, uncommon adverse reaction. Use of the drug is formally contraindicated in cases of severe pre-existing ischaemic heart disease or severe arrhythmia, but high blood pressure alone is typically not an absolute contraindication.

Q: Do official sources mention any requirements for blood tests while taking Vicetin?

Official regulatory information mandates the requirement for regular blood monitoring, specifically for Prothrombin Time/INR, only in patients who are concurrently taking the anticoagulant medicine Warfarin. This monitoring is required due to the significant risk of enhanced bleeding in this specific combination.

Q: Is Vicetin considered a controlled substance?

Official governmental classification data indicates that the active ingredient is generally not scheduled or categorized as a controlled substance under major national drug control acts or international conventions.

Q: What is the reason for the age restriction on who can use Vicetin?

The restriction prohibiting the use of the drug in children and adolescents (under 18 years old) is explicitly based on the stated lack of sufficient regulatory data concerning its safety and efficacy for this specific age group.

Q: Does Vicetin have a risk of dependence or withdrawal symptoms?

The official safety profile of the medicine is generally silent on specific statements regarding dependence or withdrawal symptoms. The substance is not classified by regulatory bodies as a drug with a high abuse potential that would require specific risk management plans.

Q: Can I take Vicetin if I have stomach sensitivity or acid reflux?

The official list of documented adverse reactions includes gastrointestinal effects such as nausea and heartburn. These are usually uncommon and mild. While these are noted as possible effects, having stomach sensitivity or acid reflux alone does not typically represent a formal contraindication for use.

Q: Can I take other pain relievers while using Vicetin?

Regulatory documents require caution when the medicine is used concomitantly with other medicines that slow blood clotting, which can include certain common pain relievers like NSAIDs. This combination may require monitoring due to a potential risk of enhanced bleeding.

Q: Is Vicetin intended for short-term or long-term use?

The oral maintenance phase of the treatment is described in official documentation as a 'long-term commitment.' Therapeutic effects are generally assessed after several months, confirming that the maintenance phase of treatment is intended to be sustained and extended.

Q: Do children ever use Vicetin for any condition?

Official regulatory documents explicitly state that the drug is contraindicated for use in children and adolescents (under 18 years old) due to the lack of sufficient safety data for this patient group. The medicine is formally contraindicated for use in this population.

Q: Does Vicetin have any interaction with herbal supplements like St. John's Wort?

While regulatory information focuses mainly on drug-drug interactions, it is noted that the medicine interacts with the CYP2C9 liver enzyme. Caution is generally warranted with herbal supplements, such as St. John's Wort, that are also known to affect liver enzymes, as they may alter the drug's processing by the body.

How should Vicetin be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory guidelines mandate specific storage and disposal protocols for Vicetin to ensure stability and environmental protection.

Storage Component Regulatory Requirement
Physical Environment Store in a secure, locked, and well-ventilated location, protected from direct sunlight, moisture, and water sources.
Handling/Packaging Keep the product in its original container and avoid unnecessary handling to prevent damage or spillage. Stacks must be stable.
Child Protection The storage area must have limited access only to authorized personnel and be strictly out of the reach of children.
Disposal Rules Do not pour down drains or into water sources. Empty containers must not be re-used and should be disposed of securely, such as by burial or incineration, according to official local guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vicetin found in:

A-Z Index: